VTVT — vTv Therapeutics Inc.

Nasdaq · Health Care · Pharmaceuticals · CIK 1641489 ·
Last close
$33.16
Market Cap
$130.61M
52W High
$43.09
52W Low
$28.75
ADV30
53,420
Next earnings
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 36,839,000 23,263,000 24,134,000 98,813,000 98,086,000 8,854,000
Dec 2025 0 -7,885,000 -7,138,000 89,899,000 88,932,000 25,462,000
Sep 2025 0 -10,699,000 -8,698,000 99,494,000 98,504,000 28,951,000
Jun 2025 0 -7,721,000 -6,046,000 26,448,000 25,922,000 24,043,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-25,255,000
Investing CF
Financing CF
$77,441,000
CapEx
Dividends Paid
Buybacks
EPS Diluted TTM
$-3.35
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-326,692,000
Inventory
Receivables
$62,000
ST Investments
EBIT TTM
$-31,701,000
Pretax Income TTM
$-31,080,000
Interest Exp TTM
$6,000
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$36,839,000
EBITDA
$-3,034,000
Free Cash Flow
$5,278,000
Enterprise Value
$328,855,200
Total Cash
$98,086,000
Total Debt
$0
Shares Out
3,938,654
Trailing EPS
$-0.79
Book Value
$5.19
ROE
-1.5%
ROA
-2.9%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -32,808,000 -26,974,000 89,899,000 25,462,000 -25,255,000
Dec 2024 1,017,000 -24,180,000 -18,462,000 38,266,000 23,965,000 -25,307,000
Dec 2023 0 -25,502,000 -20,250,000 11,018,000 29,567,000 -19,081,000
Dec 2022 2,018,000 -22,540,000 -19,164,000 33,238,000 27,399,000 -16,022,000

TTM Snapshot

Revenues TTM
$3,000,000
NetIncome TTM
$-16,785,000
OpCashFlow TTM
$0
Assets (Latest)
$38,266,000
Forward EPS
$-3.89

Peers — same industry

TickerNameMarket CapLastDaily %
DERM Journey Medical Corp $131.79M $6.12
NTHI NEONC TECHNOLOGIES HOLDINGS, INC. $133.71M $5.14
GNLX GENELUX Corp $134.97M $3.01
CNTB Connect Biopharma Holdings Ltd $135.65M $2.40
INDP Indaptus Therapeutics, Inc. $125.70M $1.11

News headlines (Yahoo Finance, 1h cache)

vTv Therapeutics Inc. (NASDAQ:VTVT) Just Beat Earnings: Here's What Analysts Think Will Happen Next
2026-05-17 13:26 · Yahoo
vTv Therapeutics (VTVT) is on the Move, Here's Why the Trend Could be Sustainable
2026-05-15 12:55 · Yahoo
vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-13 20:01 · Yahoo
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-05-08 20:15 · Yahoo
vTv Therapeutics to Participate in Upcoming May Investor Conferences
2026-05-07 12:00 · Yahoo
Wall Street Analysts See a 39.9% Upside in vTv Therapeutics (VTVT): Can the Stock Really Move This High?
2026-04-20 13:55 · Yahoo
Wall Street Analysts Think vTv Therapeutics (VTVT) Could Surge 31.58%: Read This Before Placing a Bet
2026-04-02 13:55 · Yahoo
vTv Therapeutics (VTVT) Reports $27M 2025 Net Loss Amid Cadisegliatin Advancements
2026-03-18 00:05 · Yahoo
Wall Street Analysts Believe vTv Therapeutics (VTVT) Could Rally 39.86%: Here's is How to Trade
2026-03-17 13:55 · Yahoo
vTv Therapeutics to Participate in the 38th Annual ROTH Conference
2026-03-16 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.